Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.

Thorac Cancer · 2020 · PMC7471019 · PMID 32776462

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Unfortunately, a CT scan showed a trend of progressive disease (PD) after a month, and the patient was switched to afatinib (40 mg, taken orally, daily).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.